Bamlanivimab (an Investigational Monoclonal Antibody): FDA Authorizes its Emergency Use for the Treatment of Mild to Moderate COVID-19

Bamlanivimab – Treatment of Mild to Moderate COVID-19

On November 9, 2020, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the investigational monoclonal antibody therapy bamlanivimab for the treatment of mild to moderate COVID-19 in adult and pediatric patients.

Emergency use authorization is a mechanism to provide access to an unapproved treatment when the known and potential benefits outweigh the risk.

This emergency authorization allows us to make a COVID-19 treatment available for recently diagnosed, high-risk patients – adding a valuable tool for doctors fighting the now-increasing burden of this global pandemic” said Dave Ricks, Lilly’s chairman and CEO.

Of note, bamlanivimab is authorized forpatients with positive results of direct SARS-CoV-2 viral testing who are 12 years of age and older weighing at least 40 kilograms (about 88 pounds), and who are at high risk for progressing to severe COVID-19 and/or hospitalization”. This includes those who are 65 years of age or older, or who have certain chronic medical conditions.

The EUA is based on data from BLAZE-1, a randomized, double-blind, placebo-controlled Phase 2 study in patients with recently diagnosed mild to moderate COVID-19 in the outpatient setting. Patients treated with bamlanivimab showed reduced viral load and rates of symptoms and hospitalization.

The BLAZE-1 data show bamlanivimab, when given early in the disease course, may help patients clear the virus and reduce COVID-related hospitalizations, supporting our belief that neutralizing antibodies can be an important therapeutic option for patients fighting this virus,” said Daniel Skovronsky, M.D., Ph.D., Lilly’s chief scientific officer and president of Lilly Research Laboratories.

According to The Washington Post this monoclonal antibody therapy is the first COVID-19 treatment that may eventually protect people with mild illness from developing severe disease; whereas MedPage Today emphasises that the Eli Lilly’s bamlanivimab became the first monoclonal antibody drug to treat COVID-19 patients to receive emergency use authorization (EUA) by the FDA.

As per NPR the US president got a similar medication made by Regeneron — but that product is still under review at the FDA.

About bamlanivimab

Bamlanivimab is a recombinant, neutralizing human IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19.

Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. Lilly scientists rapidly developed the antibody in less than three months after it was discovered by AbCellera and the scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center. It was identified from a blood sample taken from one of the first U.S. patients who recovered from COVID-19.

Lilly has successfully completed a Phase 1 study of bamlanivimab in hospitalized patients with COVID-19 (NCT04411628). A Phase 2 study in people recently diagnosed with COVID-19 in the ambulatory setting (BLAZE-1, NCT04427501) is ongoing. A Phase 3 study of bamlanivimab for the prevention of COVID-19 in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) is also ongoing. In addition, bamlanivimab is being tested in the National Institutes of Health-led ACTIV-2 study in ambulatory COVID-19 patients.

Limitations of Authorized Use

Bamlanivimab is not authorized for use in patients:

  • who are hospitalized due to COVID-19, OR
  • who require oxygen therapy due to COVID-19, OR
  • who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity.

Benefit of treatment with bamlanivimab has not been observed in patients hospitalized due to COVID-19. Monoclonal antibodies, such as bamlanivimab, may be associated with worse clinical outcomes when administered to hospitalized patients requiring high flow oxygen or mechanical ventilation with COVID-19.


Related stories you may like:

High Affinity Human Antibody Component Identified as a Potential Targeted SARS-Cov-2 Therapy
NIH begins the first randomized controlled trial of the combination of interferon beta-1a and remdesivir for treating COVID-19
New Evidence for Key Factors that Drive COVID-19 Severity
The European Commission Approves Remdesivir for the Treatment of Severe Cases of COVID-19
First Evidence that the Antiviral Remdesivir Shows Efficacy in an Animal Model of COVID-19
β2-Adrenoceptor-Mediated Upregulation of IL-17 May Contribute to Pulmonary Immunopathology in COVID-19
Stress, Dyshomeostasis and COVID-19 Mortality: A Big Picture View